Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nektaria Alexandri
Observed names:
Alexandri, Nektaria,
N Alexandri,
N. Alexandri
Institution:
Merck Healthcare KGaA, Darmstadt (Germany)
Observed institutions:
Inserm,
Merck KGaA, Darmstadt (Germany),
Assistance Publique – Hôpitaux de Paris,
Institut de Myologie,
Pitié-Salpêtrière Hospital,
Institut du Cerveau,
Université Pierre-et-Marie-Curie,
Merck Healthcare KGaA, Darmstadt (Germany)
show all 8
ORCID:
0000-0002-9806-8358
Observed ORCID:
0000-0002-9806-8358
OpenAlex ID:
A5007546716
Identification of an Agrin Mutation that Causes Congenital Myasthenia and Affects Synapse Function
2009
·
Caroline Huzé
, Stéphanie Bauché
, et al.
·
The American Journal of Human Genetics
·
188
PDF
Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7
2009
·
A. Ben Ammar
, F. Petit
, et al.
·
Journal of Neurology
·
85
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
2021
·
Nicola De Stefano
, Maria Pia Sormani
, et al.
·
Multiple Sclerosis Journal
·
36
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives
2021
·
Elisabeth G Celius
, Heidi Thompson
, et al.
·
Patient Preference and Adherence
·
32
PDF
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care
2019
·
Celia Oreja-Guevara
, Stanca Potra
, et al.
·
Advances in Therapy
·
30
PDF
Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier
2018
·
David Yeandle
, Peter Rieckmann
, et al.
·
Neurology and Therapy
·
30
PDF
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
2023
·
Bruno Brochet
, Alessandra Solari
, et al.
·
Multiple Sclerosis Journal
·
26
PDF
Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
2022
·
Rosa Cortese
, Marco Battaglini
, et al.
·
European Journal of Neurology
·
23
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
2021
·
Bruno Brochet
, Raymond Hupperts
, et al.
·
Multiple Sclerosis and Related Disorders
·
18
PDF
Caregiver Involvement in MS: Duty or Disruption?
2021
·
Jürg Kesselring
, Alexey Boyko
, et al.
·
Neurology and Therapy
·
15
PDF
What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation
2023
·
Sarah A. Morrow
, Paola Kruger
, et al.
·
Neurology and Therapy
·
10
PDF
Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
2019
·
Patrick Vermersch
, Jane Shanahan
, et al.
·
Neurology and Therapy
·
10
PDF
Cognitive impairment and its impact on employment: A qualitative interview-based study involving healthcare professionals and people living with multiple sclerosis
2024
·
David Yeandle
, Sarah A. Morrow
, et al.
·
Multiple Sclerosis and Related Disorders
·
8
PDF
Identification of an Agrin Mutation that Causes Congenital Myasthenia and Affects Synapse Function
2009
·
Caroline Huzé
, Stéphanie Bauché
, et al.
·
The American Journal of Human Genetics
·
8
PDF
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor
2023
·
Amit Bar-Or
, Anne H Cross
, et al.
·
Multiple Sclerosis Journal
·
7
PDF
Prevalence of disability improvement in relapsing–remitting multiple sclerosis patients treated with cladribine tablets
2022
·
Alessio Signori
, Marta Ponzano
, et al.
·
European Journal of Neurology
·
7
Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion
2016
·
Nikolaos Grigoriadis
, Michael Linnebank
, et al.
·
Expert Opinion on Pharmacotherapy
·
7
Post-Approval Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: 2023 Update
2023
·
Gavin Giovannoni
, Thomas Leist
, et al.
·
Multiple Sclerosis and Related Disorders
·
6
Oral Cladribine Capsules for Generalized Myasthenia Gravis: Design of the Actively Recruiting Phase 3 MyClad Study (P1-11.013)
2025
·
Konrad Rejdak
, James F. Howard
, et al.
·
Neurology
·
3
Clinical Outcomes in Patients With COVID-19 During Two Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis: An Update (P11-4.005)
2022
·
Victoria Yavorskaya
, Radmila Karan
, et al.
·
Neurology
·
3
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study
2026
·
Bruno Brochet
, Dawn Langdon
, et al.
·
Neurology and Therapy
·
2
PDF
Improvements in Quality of Life Over 2 Years in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: Final Analysis of CLARIFY-MS
2023
·
Alessandra Solari
, Xavier Montalban
, et al.
·
Multiple Sclerosis and Related Disorders
·
2
Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis (1925)
2021
·
Bruno Brochet
, Raymond Hupperts
, et al.
·
Neurology
·
2
THUR 172 Phase iv study of cladribine tablets and quality of life: clarify-ms
2018
·
S Schippling
, D Langdon
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
2
Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study
2026
·
Bruno Brochet
, Dawn Langdon
, et al.
·
Neurology and Therapy
·
1
PDF
Show more works
View as search
Works count:
52
Citation count:
566
H-index:
10
I10-index:
12
Year
Topic
Type